Bifidobacterium (mixed species) have been investigated for their potential role in supporting or treating Crohn's Disease, an inflammatory bowel disease characterized by chronic gastrointestinal inflammation. The scientific evidence supporting their use is limited but present, warranting a modest rating.

Several small clinical studies and pilot trials have evaluated the effects of probiotics, including mixed Bifidobacterium strains, either alone or in combination with other probiotics (such as Lactobacillus) in Crohn's Disease. Some studies suggest that these probiotics may help modify the gut microbiota, enhance mucosal barrier function, and exert anti-inflammatory effects. However, systematic reviews and meta-analyses (e.g., Derwa et al., 2017, Alimentary Pharmacology & Therapeutics) generally conclude that current evidence does not robustly support the efficacy of Bifidobacterium-containing probiotics for inducing or maintaining remission in Crohn's Disease. Most positive findings are from small, underpowered studies or from trials with mixed probiotic formulations, making it difficult to attribute benefits specifically to Bifidobacterium.

Guidelines from organizations such as the European Crohn's and Colitis Organisation (ECCO) and the American Gastroenterological Association do not currently recommend probiotics, including Bifidobacterium, as standard therapy for Crohn's Disease due to insufficient high-quality evidence. In summary, while there is some scientific rationale and preliminary clinical investigation, robust validation is lacking, and the overall evidence remains weak.